Penumbra, Inc. (PEN)
NYSE: PEN · Real-Time Price · USD
331.47
-0.95 (-0.29%)
At close: Apr 16, 2026, 4:00 PM EDT
331.47
0.00 (0.00%)
After-hours: Apr 16, 2026, 5:23 PM EDT
Penumbra Revenue
In the year 2025, Penumbra had annual revenue of $1.40B with 17.50% growth. Penumbra had revenue of $385.39M in the quarter ending December 31, 2025, with 22.14% growth.
Revenue (ttm)
$1.40B
Revenue Growth
+17.50%
P/S Ratio
9.29
Revenue / Employee
$298,652
Employees
4,700
Market Cap
13.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | 209.05M | 17.50% |
| Dec 31, 2024 | 1.19B | 136.10M | 12.86% |
| Dec 31, 2023 | 1.06B | 211.39M | 24.95% |
| Dec 31, 2022 | 847.13M | 99.54M | 13.32% |
| Dec 31, 2021 | 747.59M | 187.18M | 33.40% |
| Dec 31, 2020 | 560.41M | 13.01M | 2.38% |
| Dec 31, 2019 | 547.41M | 102.47M | 23.03% |
| Dec 31, 2018 | 444.94M | 111.17M | 33.31% |
| Dec 31, 2017 | 333.76M | 70.45M | 26.75% |
| Dec 31, 2016 | 263.32M | 77.22M | 41.50% |
| Dec 31, 2015 | 186.10M | 60.59M | 48.27% |
| Dec 31, 2014 | 125.51M | 36.66M | 41.26% |
| Dec 31, 2013 | 88.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Koninklijke Philips | 20.94B |
| Zimmer Biomet Holdings | 8.23B |
| Smith & Nephew | 6.16B |
| STERIS | 5.83B |
| DexCom | 4.66B |
| Globus Medical | 2.94B |
| Insulet | 2.71B |
| Bio-Rad Laboratories | 2.58B |
PEN News
- 3 days ago - New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients - PRNewsWire
- 5 weeks ago - 8 Stocks to Buy as Merger-Mania Takes Over - Benzinga
- 7 weeks ago - Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 2 months ago - Boston Scientific announces results for fourth quarter and full year 2025 - PRNewsWire
- 2 months ago - Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 3 months ago - Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach - Invezz
- 3 months ago - Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. - Barrons
- 3 months ago - Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing' vascular segments - Market Watch